ライフサイエンスコーパス: mass cytometry

1 cyte populations in PBMC, were analyzed with mass cytometry.

2 owerful new single-cell technologies such as mass cytometry.

3 ripheral blood mononuclear cells measured by mass cytometry.

4 d this pattern of localization using imaging mass cytometry.

5 3(+)CD4(+) T cell populations by single-cell mass cytometry.

6 llular systems has fueled the development of mass cytometry.

7 n genetically engineered cancer models using mass cytometry.

8 nd cancer cell subsets from fluorescence and mass cytometry.

9 ll carcinomas can be reliably dissected with mass cytometry.

10 ing intravital microscopy and time-of-flight mass cytometry.

11 Using mass cytometry, a high-dimensional technique that can pr

12 Here we used mass cytometry, a technique that combines single cell an

13 Like flow and mass cytometry, Abseq uses specific antibodies to detect

14 Recent advances in mass cytometry allow simultaneous measurements of up to

15 Mass cytometry allows for simultaneous measurement of >4

16 , we have employed 38-channel time-of-flight mass cytometry analysis to generate comprehensive immune

17 We combine the depth of single-cell mass cytometry and an algorithm developed to leverage th

18 Using mass cytometry and an unbiased multidimensional analytic

19 lammatory/autoimmune complications) by using mass cytometry and flow cytometry.

20 Using mass cytometry and gene expression analyses, we identifi

21 arenchymal cells were immunophenotyped using mass cytometry and gene expression analyses.

22 w, by integrating MHC tetramer multiplexing, mass cytometry and high-dimensional analyses, that neoan

23 gland biopsy specimens were also analyzed by mass cytometry and immunohistochemistry.

24 Single-cell mass cytometry and prospective isolation show that these

25 nd malignant hematopoietic cells analyzed by mass cytometry and provide recommendations for appropria

26 number of measurement channels available for mass cytometry and reduces interference with lanthanide-

27 obtained before and after challenge by CyTOF mass cytometry and RNAseq.

28 We apply our method to mass cytometry and scRNA-seq datasets, and demonstrate t

29 veral novel biological technologies, such as mass cytometry and single-cell RNA-seq (scRNA-seq), are

30 Flow cytometry and mass cytometry are complementary to each other; however,

31 le-cell analyses based on flow cytometry and mass cytometry are important for investigations of disea

32 This review will cover the basics of mass cytometry as well as outline assays developed for t

33 Existing mass cytometry barcoding approaches require time intensi

34 Here we couple mass-cytometry-based single-cell analysis with overexpre

35 Cutting-edge mass cytometry by time-of-flight (CyTOF) can profoundly

36 Mass cytometry by time-of-flight experiments allow analy

37 Here we demonstrate that mass cytometry by time-of-flight provides a label-free a

38 Here, we used a novel technology, mass cytometry by time-of-flight, to comprehensively cha

39 Furthermore, mass cytometry can enumerate AuNPs with a lower detectio

40 Novel techniques such as mass cytometry could help to identify melanoma biomarker

41 nomatous polyposis coli (APC) time-of-flight mass cytometry (CyTOF analysis).

42 e case of highly multiplexed methods such as mass cytometry (CyTOF) able to correlate the levels of m

43 Mass cytometry (CyTOF) has greatly expanded the capabili

44 Mass cytometry (CyTOF) is being used to increase the num

45 specific flow cytometry and high-dimensional mass cytometry (CyTOF) to compare BCR signaling response

46 ntracellular signals were investigated using mass cytometry (cytometry by time-of-flight), which demo

47 y review some frequently used and accessible mass cytometry data analysis tools, including principal

48 We apply ACCENSE to 35-parameter mass cytometry data from CD8(+) T cells derived from spe

49 ge of examining, visualizing, and presenting mass cytometry data has motivated continuous development

50 However, the high dimensionality of mass cytometry data introduces computational challenges

51 ruct an extensible immune reference map from mass cytometry data of cells from different organs, inco

52 w cytometry data of mouse bone marrow and to mass cytometry data of human bone marrow.

53 very methods on a large collection of public mass cytometry data sets, measuring intra-cellular signa

54 When comparing biological conditions using mass cytometry data, a key challenge is to identify cell

55 nd minimizes unwanted cell doublet events in mass cytometry data, and it reduces wet work and Ab cons

56 mining tools that have been used to analyze mass cytometry data, outline their differences, and comm

57 Using 30-channel mass cytometry data, we show that Wishbone accurately re

58 ral such tools have been applied recently to mass cytometry data.

59 pulations and highlights novel cell types in mass cytometry data.

60 machine learning to facilitate processing of mass cytometry data.

61 -SNE) algorithm, for categorical analysis of mass cytometry data.

62 et algorithm applied to the high-dimensional mass cytometry dataset identified a cross-validated mode

63 Mass cytometry defined a systems-level reference framewo

64 Multiparametric single-cell mass cytometry demonstrates that, instead of preferentia

65 Mass cytometry enables an unprecedented number of parame

66 Mass cytometry enables highly multiplexed profiling of c

67 The advent of mass cytometry enables simultaneous assessment of vastly

68 However, the success of mass cytometry experiments depends on fully understandin

69 Mass cytometry facilitates high-dimensional, quantitativ

70 Mass cytometry facilitates high-dimensional, quantitativ

71 The advent of mass cytometry has led to an unprecedented increase in t

72 Mass cytometry has recently emerged as a promising tool

73 Although mass cytometry has some shortcomings such as inability t

74 igh-throughput technologies such as flow and mass cytometry have the potential to illuminate cellular

75 ctionality probe for both flow cytometry and mass cytometry in a mimetic cell mixture and human perip

76 ched healthy controls using high-dimensional mass cytometry in combination with algorithm-guided data

77 ss some general considerations for deploying mass cytometry in the context of vaccine development.-Re

78 Application and utility of mass cytometry in vaccine development.

79 Here, we used mass cytometry including a broad range of surface marker

80 As new technologies such as mass cytometry increase the parameterization of single-c

81 Mass cytometry is a new technology that promises to exte

82 Mass cytometry is developing as a means of multiparametr

83 he combination of machine-learning tools and mass-cytometry measurements of more than 30 protein mark

84 This study combined single-cell mass cytometry of paired peripheral and umbilical cord b

85 The capabilities of mass cytometry offer expanded potential for deciphering

86 imensional single-cell technologies, such as mass cytometry, offer an opportunity to characterize sig

87 ndation for the incorporation of single-cell mass cytometry on the experimental pipeline.

88 Mass cytometry or CyTOF is an emerging technology for hi

89 multi-dimensional single-cell data, such as mass cytometry or RNA-Seq data, as input and orders cell

90 cells and their activation, demonstrated by mass cytometry phosphoproteomics.

91 When used with mass cytometry, PLAYR allowed for the simultaneous quant

92 Mass cytometry presents an exceptional opportunity to in

93 ty of results obtained from high-dimensional mass cytometry profiling data.

94 In conclusion, the use of single-cell mass cytometry provides a systems-level characterization

95 This fusion of the two technologies, termed mass cytometry, provides measurement of over 40 simultan

96 this Primer, we review the current state of mass cytometry, providing an overview of the instrumenta

97 ts were enrolled for clinical evaluation and mass cytometry quantification of 34 protein markers in b

98 parametric data generated via time-of-flight mass cytometry requires novel analytical techniques beca

99 Profiling of human NK cell subsets by mass cytometry revealed a highly similar expression patt

100 Single cell mass cytometry revealed that c-Jun activates multiple si

101 ed with TLR ligands and analyzed by means of mass cytometry simultaneously for surface marker express

102 It was initially developed for flow and mass cytometry single-cell data.

103 -cell technologies, such as multidimensional mass cytometry, single-cell gene expression, and single-

104 In this article, we review published mass cytometry studies relevant to vaccine development,

105 tometry, but also show better performance in mass cytometry than the commercially available counterpa

106 plexed transcript quantification by flow and mass cytometry that is compatible with standard antibody

107 ag cellular barcoding (MCB), which increases mass cytometry throughput by using n metal ion tags to m

108 This first application of mass cytometry to a well-stratified clinical cohort and

109 Here we use mass cytometry to analyse activated T cells in joint tis

110 We also use viSNE and mass cytometry to compare leukemia diagnosis and relapse

111 To address these issues, we utilized mass cytometry to comprehensively profile the effects of

112 Herein, we use single-cell mass cytometry to dissect the effects of graphene oxide

113 In this study, we used mass cytometry to examine the complexity of human Tregs

114 lopment, briefly compare immune profiling by mass cytometry to other systems-level technologies, and

115 Several studies have used mass cytometry to profile protective immune responses, b

116 We now describe experiments in which we used mass cytometry to simultaneously measure multiple surfac

117 from Lavin et al. and Chevrier et al. employ mass cytometry to study immune infiltrates in lung adeno

118 We used single-cell "mass cytometry" to examine healthy human bone marrow, me

119 Mass cytometry, used together with these innovative anal

120 Mass cytometry was used to investigate the effect of CMV

121 ular reprogramming at the single-cell level, mass cytometry was used to simultaneously measure marker

122 Using mass cytometry, we also find increased frequencies of im

123 Using mass cytometry, we found that NKR expression patterns di

124 By time-of-flight mass cytometry, we found that the TME was enriched in re

125 Using multiparametric phospho-flow and mass cytometry, we measured the intracellular phosphoryl

126 Using mass cytometry, we profiled surface and intracellular si

127 We used mass cytometry with extensive antibody panels to perform

128 Next, the integration of single-cell mass cytometry with genome-wide transcriptome analysis s

129 Here we show that mass cytometry with multiplex combinatorial tetramer sta

130 This study combined single-cell mass cytometry with the multiplex analysis of relevant p

131 ied by combining highly dimensional flow and mass cytometry with transcriptomic analyses.

132 We integrated mass cytometry with viSNE to map healthy and cancerous b